WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
45.58
-3.82 (-7.73%)
Oct 22, 2026, 2:05 PM HKT

WuXi Biologics Stock Forecast

Stock Price Forecast

According to 27 analysts polled by S&P Global, WuXi Biologics stock has a consensus rating of "Strong Buy" and an average price target of $60.17. The average 1-year stock price forecast is 32.01% higher than the current stock price, while the lowest is $39.32 (-13.73%) and the highest is $79.50 (+74.42%).

Price Target: $60.17 (+32.01%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$39.32$60.17$60.40$79.50
Change-13.73%+32.01%+32.51%+74.42%
* Price targets were last updated on Sep 18, 2026.

Analyst Ratings

The average analyst rating for WuXi Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMay '26Jun '26Jul '26Aug '26Sep '26Oct '26
Strong Buy171716171818
Buy555555
Hold445554
Sell000000
Strong Sell000000
Total262626272827

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
Guotai Haitong
No rating
Guotai Haitong
Buy
Maintains
$64.53
BuyMaintains$64.53+41.58%Sep 18, 2026
Morgan Stanley
Morgan Stanley
Buy
Maintains
$57.00
BuyMaintains$57.00+25.05%Sep 16, 2026
Unknown Analyst
Zhongtai Securities
No rating
Zhongtai Securities
Buy
Maintains
$61.35
BuyMaintains$61.35+34.60%Sep 5, 2026
UBS
UBS
Buy
Reiterates
$51.10 → $62.00
BuyReiterates$51.10 → $62.00+36.02%Sep 1, 2026
Unknown Analyst
CICC
No rating
CICC
Buy
Maintains
$48.00 → $60.00
BuyMaintains$48.00 → $60.00+31.64%Aug 28, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
25.69B
from 21.79B
Increased by 17.89%
Revenue Next Year
30.71B
from 25.69B
Increased by 19.56%
EPS This Year
1.55
from 1.33
Increased by 16.38%
EPS Next Year
1.86
from 1.55
Increased by 20.07%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
10.29B15.27B17.03B18.68B21.79B25.69B
Revenue Growth
83.35%48.38%11.56%9.63%16.68%17.89%
Gross Profit
4.83B6.72B6.83B7.65B10.02B11.81B
Gross Margin
46.93%44.04%40.08%40.97%45.98%45.97%
Operating Income
3.17B4.35B3.93B4.59B6.65B8.25B
Net Income
3.39B4.42B3.40B3.36B4.91B5.69B
EPS
----1.331.55
EPS Growth
----18.75%16.38%
Forward PE
77.9137.4122.7117.0921.6425.05
Free Cash Flow
----2.30B2.22B
No. Analysts
-----23
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High26.8B
Avg25.7B
Low25.3B

Revenue Growth

Revenue Growth202620272028
High
22.9%
Avg
17.9%
Low
16.0%

EPS Forecast

EPS202620272028
High1.80
Avg1.55
Low1.30

EPS Growth

EPS Growth202620272028
High
35.3%
Avg
16.4%
Low
-2.3%